Molecular weight fibrinogen variants alter gene expression and functional characteristics of human endothelial cells

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2800-2809

  Weijers, E M ^a   Van Wijhe, M H ^a   Joosten, L ^a   Horrevoets, A J G ^a   De Maat, M P M ^b   Van Hinsbergh, V W M ^a   Koolwijk, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; DLL4; Endothelial cell; Fibrin; Fibrinogen; Microarray

Indexed keywords

ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BETA1 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; FIBRIN; FIBRINOGEN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH RECEPTOR; PROTEIN DLL4; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HEY 1; TRANSCRIPTION FACTOR HEY 2; UNC5B PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRINOGEN; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; INTEGRINS; MOLECULAR WEIGHT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 78650009477     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04096.x     Document Type: Article

References (45)

1. Laurens N, Koolwijk P, De Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-9.
2. Van Hinsbergh VWM, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 716-28.
3. Clark RA. Fibrin is a many splendored thing. J Invest Dermatol 2003; 121: xxi-xxii.
4. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
5. De Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12: 377-83.
6. Holm B. Nilsen DW, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-76.
7. Holm B, Godal HC. Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called 'acute phase' by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res 1984; 35: 279-90.
8. Holm B, Nilsen DW, Godal HC. Evidence that low molecular fibrinogen (LMW) is formed in man by degradation of high molecular weight fibrinogen (HMW). Thromb Res 1986; 41: 879-84.
9. Nakashima A, Sasaki S, Miyazaki K, Miyata T, Iwanaga S. Human fibrinogen heterogeneity: the COOH-terminal residues of defective A alpha chains of fibrinogen II. Blood Coagul Fibrinolysis 1992; 3: 361-70.
10. Weisel JW, Medved L. The structure and function of the alpha C domains of fibrinogen. Ann N Y Acad Sci 2001; 936: 312-27.
11. Kaijzel EL, Koolwijk P, Van Erck MG, Van Hinsbergh VWM, De Maat MP. Molecular weight fibrinogen variants determine angiogenesis rate in a fibrin matrix in vitro and in vivo. J Thromb Haemost 2006; 4: 1975-81.
12. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
13. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-42.
14. Collen A, Koolwijk P, Kroon M, Van Hinsbergh VWM. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 1998; 2: 153-65.
15. Van Hinsbergh VWM. Impact of endothelial activation on fibrinolysis and local proteolysis in tissue repair. Ann N Y Acad Sci 1992; 667: 151-62.
16. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990; 32: 319-27.
17. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
18. Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H, Allen ED, Hiraoka N, Weiss SJ. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 2002; 195: 295-308.
19. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115(Pt 17): 3427-38.
20. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003; 60: 1135-57.
21. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-53.
22. Martinez-Lemus LA, Wu X, Wilson E, Hill MA, Davis GE, Davis MJ, Meininger GA. Integrins as unique receptors for vascular control. J Vasc Res 2003; 40: 211-33.
23. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-21.
24. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J Biol Chem 1997; 272: 5360-6.
25. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 105-19.
26. Laurens N, Engelse MA, Jungerius C, Lowik CW, Van Hinsbergh VWM, Koolwijk P. Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix. Angiogenesis 2009; 12: 275-85.
27. Smith RA, Rooney MM, Lord ST, Mosesson MW, Gartner TK. Evidence for new endothelial cell binding sites on fibrinogen. Thromb Haemost 2000; 84: 819-25.
28. Thiagarajan P, Rippon AJ, Farrell DH. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry 1996; 35: 4169-75.
29. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-107.
30. Van Hinsbergh VWM, Sprengers ED, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost 1987; 57: 148-53.
31. Koolwijk P, Van Erck MG, De Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, Van Hinsbergh VWM. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.
32. Fledderus JO, Boon RA, Volger OL, Hurttila H, Yla-Herttuala S, Pannekoek H, Levonen AL, Horrevoets AJ. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 1339-46.
33. Larrivee B, Freitas C, Trombe M, Lv X, Delafarge B, Yuan L, Bouvree K, Breant C, Del Toro R, Brechot N, Germain S, Bono F, Dol F, Claes F, Fischer C, Autiero M, Thomas JL, Carmeliet P, Tessier-Lavigne M, Eichmann A. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev 2007; 21: 2433-47.
34. Freitas C, Larrivee B, Eichmann A. Netrins and UNC5 receptors in angiogenesis. Angiogenesis 2008; 11: 23-9.
35. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-7.
36. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007; 7: 327-31.
37. Thurston G, Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008; 99: 1204-9.
38. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, Dupuy E. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006; 66: 8501-10.
39. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007; 67: 11244-53.
40. Collen A, Maas A, Kooistra T, Lupu F, Grimbergen J, Haas FJ, Biesma DH, Koolwijk P, Koopman J, Van Hinsbergh VWM. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-80.
41. Segarra M, Williams CK, Sierra ML, Bernardo M, McCormick PJ, Maric D, Regino C, Choyke P, Tosato G. Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 2008; 112: 1904-11.
42. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-80.
43. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107: 931-9.
44. Yoneya T, Tahara T, Nagao K, Yamada Y, Yamamoto T, Osawa M, Miyatani S, Nishikawa M. Molecular cloning of delta-4, a new mouse and human Notch ligand. J Biochem 2001; 129: 27-34.
45. Cavalcanti-Adam EA, Volberg T, Micoulet A, Kessler H, Geiger B, Spatz JP. Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J 2007; 92: 2964-74.